Paul Saladino· MD
our meta-analysis of clinical events registered on clinicaltrials.gov did not show that pcsk9 inhibitors improve cardiovascular health evolocumab it's their monoclonal antibodies increased the risk of all-cause mortality
Loading…
We can't find evidence that holds up here. Proponents are reasoning from mechanism or analogy rather than direct human data, and the most credible skeptics raise objections we can't dismiss.
our meta-analysis of clinical events registered on clinicaltrials.gov did not show that pcsk9 inhibitors improve cardiovascular health evolocumab it's their monoclonal antibodies increased the risk of all-cause mortality
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
our meta analysis of clinical trials did not show that pcsk9 Inhibitors improve cardiovascular health evolocumab increased the risk of all cause mortality